Bg Medicine Stock Performance
| BGMD Stock | USD 0.0001 0.00 0.00% |
The firm owns a Beta (Systematic Risk) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and BG Medicine are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days BG Medicine has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound primary indicators, BG Medicine is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
BGMD |
BG Medicine Relative Risk vs. Return Landscape
If you would invest 0.01 in BG Medicine on November 4, 2025 and sell it today you would earn a total of 0.00 from holding BG Medicine or generate 0.0% return on investment over 90 days. BG Medicine is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than BGMD, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BG Medicine Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BG Medicine for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BG Medicine can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| BG Medicine generated a negative expected return over the last 90 days | |
| BG Medicine has some characteristics of a very speculative penny stock | |
| BG Medicine has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.57 M. Net Loss for the year was (5.3 M) with profit before overhead, payroll, taxes, and interest of 1.06 M. | |
| BG Medicine currently holds about 1.52 M in cash with (3.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.14, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: American Tower Stock Dips While Market Gains Key Facts - Yahoo Finance |
BG Medicine Fundamentals Growth
BGMD Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of BG Medicine, and BG Medicine fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BGMD Pink Sheet performance.
| Return On Equity | -9.03 | |||
| Return On Asset | -0.76 | |||
| Operating Margin | (2.86) % | |||
| Current Valuation | 545.97 K | |||
| Shares Outstanding | 11.37 M | |||
| Price To Earning | (0.06) X | |||
| Price To Sales | 0.35 X | |||
| Revenue | 1.57 M | |||
| EBITDA | (4.39 M) | |||
| Cash And Equivalents | 1.52 M | |||
| Cash Per Share | 0.14 X | |||
| Debt To Equity | 5.31 % | |||
| Book Value Per Share | (0.17) X | |||
| Cash Flow From Operations | (3.67 M) | |||
| Earnings Per Share | (0.72) X | |||
| Total Asset | 2.13 M | |||
| Retained Earnings | (161.49 M) | |||
| Current Asset | 1.95 M | |||
| Current Liabilities | 1.18 M | |||
About BG Medicine Performance
By analyzing BG Medicine's fundamental ratios, stakeholders can gain valuable insights into BG Medicine's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BG Medicine has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BG Medicine has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts. BG MEDICINE operates under Medical Instruments Supplies classification in the United States and is traded on PNK Exchange. It employs 5 people.Things to note about BG Medicine performance evaluation
Checking the ongoing alerts about BG Medicine for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for BG Medicine help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BG Medicine generated a negative expected return over the last 90 days | |
| BG Medicine has some characteristics of a very speculative penny stock | |
| BG Medicine has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.57 M. Net Loss for the year was (5.3 M) with profit before overhead, payroll, taxes, and interest of 1.06 M. | |
| BG Medicine currently holds about 1.52 M in cash with (3.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.14, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: American Tower Stock Dips While Market Gains Key Facts - Yahoo Finance |
- Analyzing BG Medicine's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BG Medicine's stock is overvalued or undervalued compared to its peers.
- Examining BG Medicine's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BG Medicine's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BG Medicine's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BG Medicine's pink sheet. These opinions can provide insight into BG Medicine's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BGMD Pink Sheet analysis
When running BG Medicine's price analysis, check to measure BG Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BG Medicine is operating at the current time. Most of BG Medicine's value examination focuses on studying past and present price action to predict the probability of BG Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BG Medicine's price. Additionally, you may evaluate how the addition of BG Medicine to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |